RDHL has been the subject of a number of other research reports. FBR & Co reiterated a buy rating on shares of RedHill Biopharma Ltd – in a report on Wednesday, April 5th. Zacks Investment Research upgraded RedHill Biopharma Ltd – from a sell rating to a buy rating and set a $12.00 price objective for the company in a report on Thursday, January 19th.
Shares of RedHill Biopharma Ltd – (NASDAQ:RDHL) traded up 0.10% on Thursday, reaching $9.94. 22,811 shares of the company were exchanged. The company’s 50-day moving average price is $9.89 and its 200 day moving average price is $10.35. RedHill Biopharma Ltd – has a 12 month low of $8.77 and a 12 month high of $16.54. The company’s market cap is $169.05 million.
RedHill Biopharma Ltd – (NASDAQ:RDHL) last announced its earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.14. On average, equities research analysts expect that RedHill Biopharma Ltd – will post ($2.19) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “HC Wainwright Analysts Give RedHill Biopharma Ltd – (RDHL) a $33.00 Price Target” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.chaffeybreeze.com/2017/05/19/hc-wainwright-analysts-give-redhill-biopharma-ltd-rdhl-a-33-00-price-target-updated.html.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new position in shares of RedHill Biopharma Ltd – during the first quarter valued at about $101,000. Family Management Corp acquired a new stake in shares of RedHill Biopharma Ltd – during the first quarter valued at about $163,000. Penserra Capital Management LLC increased its stake in shares of RedHill Biopharma Ltd – by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 7,647 shares during the period. Oppenheimer & Co. Inc. increased its stake in shares of RedHill Biopharma Ltd – by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 6,172 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of RedHill Biopharma Ltd – during the fourth quarter valued at about $266,000. 11.84% of the stock is currently owned by institutional investors and hedge funds.
About RedHill Biopharma Ltd –
RedHill Biopharma Ltd. is a biopharmaceutical company. The Company is focused on the development and commercialization of clinical-stage, orally-administered, small molecule drugs for the treatment of gastrointestinal (GI) and inflammatory diseases and cancer. Its seven clinical-stage therapeutic candidates include RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA, MESUPRON and RIZAPORT and related research and development programs.
Receive News & Ratings for RedHill Biopharma Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd - and related companies with MarketBeat.com's FREE daily email newsletter.